Search

This report has been compiled as part of the IEA HPT Annex 58 about High-Temperature Heat Pumps (HTHP). The Annex is structured into the following 5 tasks: -Task 1: Technologies – State of the art and ongoing developments for systems and components -Task 2: Integration Concepts – Development of best practice integration concepts for promising application cases -Task 3: Applications and Transition – Strategies for the conversion to HTHP-based process heat supply -Task 4: Definition and testing of HP specifications – Recommendations for defining and testing of specifications for high-temperature heat pumps in commercial projects -Task 5: Dissemination The overall objective of the Annex is to provide an overview of the technological possibilities and applications as well as to develop best practice recommendations and strategies for the transition towards heat pump-based process heat supply. The intention is to improve the understanding of the technology’s potential among various stakeholders, such as manufacturers, potential end-users, consultants, energy planners, and policy makers. In addition, the Annex aims to provide supporting material to facilitate and enhance the transition to a heat pump-based process heat supply for industrial applications. This will be achieved by the following sub-objectives: -Provide an overview of the technology, including the most relevant systems and components that are commercially available and under development (Task 1). -Identify technological bottlenecks and clarify the need for technical developments regarding components, working fluids, and system design (Task 1). -Present best practice system solutions for a range of applications to underline the potential of HTHPs (Task 2). -Present strategies for the transition to heat-pump-based process heat supply (Task 3). -Enhance the information basis about industrial heat pumps, potential applications

Objectives We conducted a phase 2 trial to assess the feasibility of interval cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in patients with stage III and IV pleural ovarian carcinoma in first-line treatment with no macroscopic residual disease after surgery. Methods Patients could be treated either with primary CS with HIPEC followed by 6 conventional cycles of chemotherapy or with 3 or 4 cycles of neoadjuvant chemotherapy before CS with HIPEC and 3 postoperative chemotherapy cycles. Hyperthermic intraperitoneal chemotherapy was performed with cisplatin (50 mg/m2) for 60 minutes, only in case of complete cytoreduction. Results Nineteen patients were included in the study, and they all underwent neoadjuvant chemotherapy before CS. Sixteen patients underwent complete CS with HIPEC. There was no mortality, and morbidity of CS with HIPEC was acceptable. The HIPEC procedure did not prevent the administration of the standard first-line treatment. In the 16 patients who underwent CS with HIPEC, the outcomes were very good. Conclusion Our study shows an acceptable toxicity of adding HIPEC to the standard first-line treatment in patients with stage III ovarian carcinoma treated with interval CS. Further studies are needed to confirm the role of HIPEC in the treatment of ovarian carcinoma., SCOPUS: ar.j, info:eu-repo/semantics/published

SCOPUS: ar.j, info:eu-repo/semantics/published